Delving into the Latest Updates on CHAIN Biotechnology Ltd. with Synapse

Overview

Tags

Digestive System Disorders

Neoplasms

Therapeutic vaccine

Live biotherapeutic products

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Neoplasms	1

Top 5 Drug Type	Count

Live biotherapeutic products	1
Therapeutic vaccine	1

BACKGROUNDMicrobial formation of acetone, isopropanol, and butanol is largely restricted to bacteria belonging to the genus Clostridium. This ability has been industrially exploited over the last 100 years. The solvents are important feedstocks for the chemical and biofuel industry. However, biological synthesis suffers from high substrate costs and competition from chemical synthesis supported by the low price of crude oil. To render the biotechnological production economically viable again, improvements in microbial and fermentation performance are necessary. However, no comprehensive comparisons of respective species and strains used and their specific abilities exist today.RESULTSThe genomes of a total 30 saccharolytic Clostridium strains, representative of the species Clostridium acetobutylicum, C. aurantibutyricum, C. beijerinckii, C. diolis, C. felsineum, C. pasteurianum, C. puniceum, C. roseum, C. saccharobutylicum, and C. saccharoperbutylacetonicum, have been determined; 10 of them completely, and compared to 14 published genomes of other solvent-forming clostridia. Two major groups could be differentiated and several misclassified species were detected.CONCLUSIONSOur findings represent a comprehensive study of phylogeny and taxonomy of clostridial solvent producers that highlights differences in energy conservation mechanisms and substrate utilization between strains, and allow for the first time a direct comparison of sequentially selected industrial strains at the genetic level. Detailed data mining is now possible, supporting the identification of new engineering targets for improved solvent production.

01 Apr 2017·Industrial Biotechnology

Making Clostridia Great Again

Author: Minton, Nigel ; Heeg, Daniela ; Green, Edward

Nature Communications

Prey killing without invasion by Bdellovibrio bacteriovorus defective for a MIDAS-family adhesin

Article

Author: Radford, Paul ; Huwiler, Simona G ; Till, Rob ; Lovering, Andrew L ; Elizabeth Sockett, R ; Lambert, Carey ; Tyson, Jess

AbstractThe bacterium Bdellovibrio bacteriovorus is a predator of other Gram-negative bacteria. The predator invades the prey’s periplasm and modifies the prey’s cell wall, forming a rounded killed prey, or bdelloplast, containing a live B. bacteriovorus. Redundancy in adhesive processes makes invasive mutants rare. Here, we identify a MIDAS adhesin family protein, Bd0875, that is expressed at the predator-prey invasive junction and is important for successful invasion of prey. A mutant strain lacking bd0875 is still able to form round, dead bdelloplasts; however, 10% of the bdelloplasts do not contain B. bacteriovorus, indicative of an invasion defect. Bd0875 activity requires the conserved MIDAS motif, which is linked to catch-and-release activity of MIDAS proteins in other organisms. A proteomic analysis shows that the uninvaded bdelloplasts contain B. bacteriovorus proteins, which are likely secreted into the prey by the Δbd0875 predator during an abortive invasion period. Thus, secretion of proteins into the prey seems to be sufficient for prey killing, even in the absence of a live predator inside the prey periplasm.

100 Deals associated with CHAIN Biotechnology Ltd.

Login to view more data

100 Translational Medicine associated with CHAIN Biotechnology Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 24 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

2

1

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

CHN-1	Inflammatory Bowel Diseases More	Preclinical
HPV vaccine(CHAIN Biotech)	Human Papillomavirus-Related Solid Tumors More	Preclinical
CHN-2	Clostridium Infections More	Pending